Ambrilia Biopharma Inc. (Ambrilia) is a biopharmaceutical company engaged in discovery and development of treatments for viral diseases and cancer. Ambrilia’s product pipeline includes: C2L octreotide, a formulation of an existing drug to treat acromegaly; a new three-month release formulation, as well as a new one-month release formulation of goserelin to treat prostate cancer; PCK3145, a therapeutic non-toxic peptide for the treatment of hormone-resistant prostate cancer; NGR-Delivery Technology, a targeted delivery technology for cancer. Ambrilia also has a biomarker for the diagnostic and prognostic of prostate cancer, PSP. The antiviral pipeline is comprised of human immunodeficiency virus (HIV) protease, integrase and entry inhibitors, Hepatitis C virus (HCV) inhibitors and anti-influenza compounds.